-
FDA Signals Move to Ease Restrictions on Certain Peptides
The FDA is reportedly moving toward loosening restrictions on certain peptide compounds, a shift that could expand access and support further development in the peptide space.
-
Oral GLP-1 Contender: CU Anschutz Explores Orforglipron for Weight Loss
Researchers at the University of Colorado Anschutz Medical Campus are studying orforglipron, an investigational oral GLP-1 medication that could offer a needle-free alternative for weight management.
-
FDA Advisory Panel Backs Continued Access to Compounded Peptides
An FDA advisory panel has voted to allow certain unapproved peptides to remain available through compounding pharmacies, preserving a pathway for patients and providers who rely on these customized preparations.
-
FDA Advisory Panel Backs Easing Restrictions on Six Popular Peptides
An FDA advisory committee has voiced support for loosening restrictions on six peptides, a move that could expand access for patients and practitioners. The decision now heads toward further regulatory review.
-
Tesamorelin: A Standout Example of an FDA-Approved Peptide Success Story
Tesamorelin’s FDA approval highlights how growth hormone-releasing hormone (GHRH) analogs have moved from research interest into legitimate, regulated clinical use. Its journey offers an encouraging case study for the broader peptide field.
-
US Health Panel Eases Restrictions on Popular Peptides, Expanding Access
A U.S. health advisory panel has voted to loosen restrictions on several peptides that have grown popular online, potentially opening the door to wider availability through compounding pharmacies.
-
Lilly Advances Toward FDA Approval for Retatrutide, a Promising Triple-Action Obesity Peptide
Eli Lilly plans to submit new clinical data to the FDA for retatrutide, an investigational triple-hormone-receptor peptide showing strong results in obesity research.
-
FDA Advisory Panel Recommends Expanding Access to Six Peptides Through Compounding
An FDA advisory panel has voted to support the inclusion of six peptides on the agency’s approved list for pharmacy compounding, potentially expanding patient access to these therapies. The recommendation marks a meaningful step toward broader availability under proper regulatory oversight.
-
New Phase III Trial Explores Combining Cetuximab with Pembrolizumab for Recurrent Head and Neck Cancer
A new phase III clinical trial is investigating whether adding the monoclonal antibody cetuximab to standard pembrolizumab treatment can improve outcomes for patients with recurrent or metastatic head and neck squamous cell carcinoma.
-
New Clinical Trial Explores Amivantamab Combinations for Early-Stage EGFR-Mutated Lung Cancer
A newly launched study is investigating whether pairing amivantamab with lazertinib or standard chemotherapy can help shrink resectable EGFR-mutated non-small cell lung cancer before surgery. The trial reflects ongoing efforts to improve treatment options for patients with this common lung cancer subtype.